Expert interview - 05/07/2023 Every tenth of a degree matters when it comes to mitigating the consequences of global warming: sustainability measures in the laboratory The life sciences sector consumes huge quantities of energy and resources. This needs to change and we have to think differently. But how and where can sustainability measures be sensibly applied in the laboratory without compromising the quality of research results? Dr. Kerstin Hermuth-Kleinschmidt, owner of NIUB-Nachhaltigkeitsberatung, a company from Freiburg that focuses on sustainability in life sciences, tells BIOPRO how this can be done.
Predicting the success of cancer treatment - 20/06/2023 Focusing on gut microbiome for CAR T-cell therapy Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.
Press release - 20/06/2023 CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demonstrated relevance in glioblastoma. A first data readout is expected in the second half of 2024.
Press release - 20/06/2023 Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the Lungs in Future KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.
Reduced immunosuppression possible in transplantations - 05/06/2023 Modified immune cells produce donor-specific tolerance Traditionally, transplant recipients have had to take immunosuppressive medication for life to prevent organ rejection. However, there are considerable side effects involved. Using modified immune cells (MICs), TolerogenixX GmbH from Heidelberg has now managed to generate donor-specific tolerance in recipients of living kidney transplants without suppressing the overall immune system.
Detecting drug resistance of tumour cells - 25/05/2023 AI-assisted diagnostics declares war on lung cancer Lung cancer is one of the most common cancers and has a particularly high mortality rate. A significant challenge in treating this disease lies in the resistance of lung tumours to conventional drug therapies, rendering chemotherapy ineffective. There is hope on the horizon as a team of experts from Baden-Württemberg has joined forces to develop an innovative AI-supported test procedure that paves the way for individualised therapy approaches.
Press release - 16/05/2023 Mast cells have an important impact on the development of chronic myeloid leukemia Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20 percent of all adult leukemia cases. A research team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg has now demonstrated for the first time that mast cells play a crucial role in the development of CML.
Press release - 16/05/2023 First company in the world to offer preclinical drug tests for children with cancer The recently established ITCC-P4 gGmbH provides academic institutions and pharmaceutical companies with a comprehensive repertoire of modern laboratory models of pediatric tumors. The aim is to systematically test new treatment options for children and adolescents with cancer and to contribute data to regulatory approval processes in order to make the development of new cancer therapies for children and adolescents more attractive.
Optogenetic cell analysis - 15/05/2023 opto biolabs: how frustration and inventiveness led to the establishment of a company When she found she had no suitable illumination devices for her doctoral thesis, Dr. Kathrin Brenker simply created her own customised adapters and founded a company called opto biolabs. Now, Brenker and company co-founder Luis Köbele sell two different types of devices. The main goal is to equip laboratories with illumination technologies that allow optogenetics methods to be used to accelerate development of optogenetic therapeutics.
"Programmable" polymer materials - 24/04/2023 Medicine of the future: intelligent 4D polymers from the printer It is impossible to imagine medicine without 3D printing, which can be used to make implants or for culturing cells and tissues. It is now possible for 3D objects to be given an added dimension, namely an ability to make simple autonomous movements, by changing their size. Researchers at Heidelberg University have been able to produce microscopically small 4D structures from intelligent polymers that can be tailored to individual requirements.
Press release - 23/03/2023 Targeted computer modelling to accelerate antiviral drug development Effective drugs against viral diseases like COVID-19 are urgently needed now and in the future. The emergence of viral mutants and yet unknown viruses could push vaccines to their limits. The DZIF scientist and bioinformatician Andreas Dräger from the University of Tübingen is working on a computer-based method that can help to accelerate the time-consuming identification and development of antiviral agents. Using a novel analysis technique that…
Development of anti-tumour agents - 20/03/2023 Targeting the protective shield of cancers Cancer cells have different mechanisms to help them escape destruction by the immune system. Solid tumours, for example, are often surrounded by a protective layer of lactate, which has a strong immunosuppressive effect. WMT AG from Heidelberg is developing small drug molecules that reduce lactate production and thus make cancer cells vulnerable to immune system attacks.